Indian Journal of Chemical Technology

Open Access Open Access  Restricted Access Subscription Access

Biocompatible Dendrimer for the Solubility Enhancement and Sustained Release Of Piroxicam


Affiliations
1 Department of Physical Chemistry, School of Chemical Sciences, University of Madras,Guindy Campus, Chennai 600 025, Tamil Nadu, India
 

Piroxicam (PRM) a nonsteroidal anti-inflammatory medication is an oxicam-class used orally to treat gout, arthritis, and other inflammatory diseases. However, its poor aqueous solubility and bioavailability has hampered further clinical applications in health industries. This work emphasize on development of four types of functionalised biocompatible dendrimer with generation 0 and 1and examine its solubility, drug release and antibacterial activity. The maximum solubility enhancement of PRM up to 48 folds has been achieved by PAMAM (G1)-CH3 at a concentration of 9.9×10-4 M. The in vitro release gets sustained up to 450 mins for releasing 90% of drug from PAMAM (G1)-COCH3 compared to its parent dendrimer which is 120 min. The anti-bacterial studies reflected that when dendrimers are used as drug carriers, the inherent property of drug is not disturbed, instead the activity has been increased. The activity interms of zone of inhibition results in 1.5-2.0 folds increase and it is more pronounced in the case of B. subtilis rather than E.coli. This observation indicates evidence that dendrimer and their derivatives are promising candidates for drug solubility enhancer and effective delivery of drugs with drastic reduction in side effect and improved efficiency.

Keywords

Antibacterial activity, PAMAM dendrimer, Piroxicam (PRM), Solubility enhancement, Sustained release
User
Notifications
Font Size

  • Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung K A, Ekbom A, Drugs, 64 (2004) 2315.

  • Izdes S, Orhun S, Turanli S, Erkilic E & Kanbak O, Anesth Analg, 97 (2003) 1016.

  • Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A & Nicotra F, Int J Med Toxicol Drug Exp, 35 (2012) 1127.

  • Jinno J, Oh D, Crison J R & Amidon G L, J Pharm Sci, 89 (2000) 268.

  • Pushkar S, Philip A, Pathak K & Pathak D, Indian J Pharm Educ Res,40(2006) 153.

  • Sakthivel T & Florence A T, Int J Pharm, 254 (2003) 23.

  • Gupta U, Agashe H B, Asthana A & Jain N K, Biomacromolecules, 7 (2006) 649.

  • Mahapatra A K, Murthy P N, Swadeep B & Swain R P, Int J Pharm Tech Res, 6 (2014) 546.

  • Tang J, Sun J & He Z G, Curr Drug Ther, 2 (2008) 85.

  • Mishra V, Nayak P, Yadav N, Singh M & Tambuwala M M, Expert Opin Drug Deliv, 18 (2021) 315.

  • Yiyun C, Zhenhua X, Minglu M & Tonguen X, J Pharma Sci, 97 (2008) 123.

  • Hawker C & Fréchet J M J, J Chem Soc Chem Commun, 15 (1990) 1010.

  • AL-Timimi Z, Heliyon, 7 (2021) 06863.

  • Al-Timimi Z, Int J Low Extrem Wounds, 21 (2022) 640.

  • Barakat D A, Al-Abbas G & Al-Timimi Z, Iraqi Laser Sci J, 1 (2019) 21.

  • Grainger D W & Okano T, Adv Drug Delivery Rev, 55 (2003) 311.

  • Emanuele AD & Attwood D, Adv Drug Deliv Rev, 57 (2005) 2147.

  • Jain K, Kesharwani P, Gupta U & Jain N K, Int J Pharm, 394 (2010)122.

  • Duncan R & Izzo L, Adv Drug Deliv Rev, 57 (2005) 2215.

  • Smith P E, Brender J R, Durr U H, Xu J, Mullen D G & Banaszak Holl M M, J Am Chem Soc, 132(2010) 8087.

  • Zhang Y, Sun Y, Xu X, Zhang X, Zhu H & Huang L, J Med Chem, 53(2010) 3262.

  • MajorosI J, Thomas T P, Mehta C B & Baker J R, J Med Chem, 48 (2005) 5892.

  • Roy R & Baek M G, J Biotechnol, 90(2002) 291.

  • Kolhatkar R, Kitchens K, Swaan P & Ghandehari H, Bioconjug Chem, 18 (2007) 2054.

  • Zhang Y, Sun Y, Xu X, Zhu H, Huang L & Zhang X, Bioorg Med Chem Lett, 20(2010) 927.

  • Murugan E, Geetha Rani D P, Srinivasan K & Muthumary J, Expert Opin Drug Delivery, 10 (2013) 1319.

  • Murugan E, Geetha Rani D P & Yogaraj V, Colloids Surf B Biointerfaces, 114 (2014) 21.

  • Murugan E, Yogaraj V, Geetha Rani D P & Alok Kumar S, RSC Adv, 5 (2015) 106461.

  • Yogaraj V, Gowtham G, Akshata C R, Manikandan R, Murugan E & Arumugam M, J Drug Deliv Sci Technol, 58 (2020) 101785.

  • Martin A, Bustamante P, Chun AHC.,Physical Pharmacy, 4th Edition, B.I. Waverly Pvt. Ltd. New Delhi 274 (1999) 53.

  • Ventura C A, Giannone I, Paolino D, Pistora V, Corasaro A & Puglisi G, Eur J Med Chem, 40 (2005) 624.

  • Shi X Y, Wang S H, Van Antwerp M E, Chen X & Baker J R, Analyst, 134 (2009) 1373.

  • Shi X Y, Wang S H, Meshinchi S, Van Antwerp M E, Bi X D, Lee I H & Baker J R, Small, 3 (2007) 1245.

  • Cheng Y Y, Li Y W, Wu Q L, Zhang J H & Xu T W, Eur J Med Chem, 44 (2009) 2219.

  • Komiyana M & Bender M L J, Am Chem Soc, 100 (1977) 2259.

  • Yang W J, Li Y W, Cheng Y Y, Wu Q L, Wen L P, Xu T W J, Pharm Sci, 98 (2009) 1075.

  • Liu J Y, Pang Y, Huang W, Zhu X Y, Zhou Y F & Yan, D Y, Biomaterials, 31 (2010) 1334.

  • Brand T, Cabrita E J & Berger S, Prog Nucl Magn Reson Spectrosc, 46 (2005) 159.

  • Chai M H, Holley A K & Kruskamp M, Chem Commun, (2007) 168.

  • Hao H X, Wang J K & Wang Y L J, Chem Eng Data, 49 (2004) 1697.

  • Nirschl R P, Rodin D M, Ochiai D H & Maartmann-Moe C, Am J Sports Med, 31 (2003) 189.


Abstract Views: 78

PDF Views: 61




  • Biocompatible Dendrimer for the Solubility Enhancement and Sustained Release Of Piroxicam

Abstract Views: 78  |  PDF Views: 61

Authors

E Murugan
Department of Physical Chemistry, School of Chemical Sciences, University of Madras,Guindy Campus, Chennai 600 025, Tamil Nadu, India
V Yogaraj
Department of Physical Chemistry, School of Chemical Sciences, University of Madras,Guindy Campus, Chennai 600 025, Tamil Nadu, India
D P Geetharani
Department of Physical Chemistry, School of Chemical Sciences, University of Madras,Guindy Campus, Chennai 600 025, Tamil Nadu, India

Abstract


Piroxicam (PRM) a nonsteroidal anti-inflammatory medication is an oxicam-class used orally to treat gout, arthritis, and other inflammatory diseases. However, its poor aqueous solubility and bioavailability has hampered further clinical applications in health industries. This work emphasize on development of four types of functionalised biocompatible dendrimer with generation 0 and 1and examine its solubility, drug release and antibacterial activity. The maximum solubility enhancement of PRM up to 48 folds has been achieved by PAMAM (G1)-CH3 at a concentration of 9.9×10-4 M. The in vitro release gets sustained up to 450 mins for releasing 90% of drug from PAMAM (G1)-COCH3 compared to its parent dendrimer which is 120 min. The anti-bacterial studies reflected that when dendrimers are used as drug carriers, the inherent property of drug is not disturbed, instead the activity has been increased. The activity interms of zone of inhibition results in 1.5-2.0 folds increase and it is more pronounced in the case of B. subtilis rather than E.coli. This observation indicates evidence that dendrimer and their derivatives are promising candidates for drug solubility enhancer and effective delivery of drugs with drastic reduction in side effect and improved efficiency.

Keywords


Antibacterial activity, PAMAM dendrimer, Piroxicam (PRM), Solubility enhancement, Sustained release

References